Research on the liver in health and disease. Covers liver-disease subtypes, the liver's role in circadian timing, targeted therapies, and cell regulation.
A new mouse model has shown reduced blood glucose levels and lower serum insulin, indicating improved glucose tolerance in the liver. The study found that Gab1 acts as a negative regulator on insulin signal strength in the liver, suggesting potential therapeutic targets for type 2 diabetes.
Researchers at Wake Forest University School of Medicine have found that the liver is the main source of high-density lipoprotein (HDL), or 'good' cholesterol. This discovery could lead to new treatments for raising HDL levels, particularly in individuals with less severe cholesterol disorders.
Researchers have discovered a new role for NKT cells in the liver, which crawl along vessel walls to detect foreign molecules and trigger an immune response. This finding offers a potential new approach to treating hepatitis by manipulating the NKT cell's behavior and reducing inflammation.
Scientists discover NKT cells primarily patrol liver blood vessels, showcasing agility and rapid movement. The study reveals surprises about NKT cell behavior, including their ability to survive without the CXCR6 gene.
The NASH Clinical Research Network is launching two trials to treat nonalcoholic steatohepatitis (NASH), a leading cause of cirrhosis in the US. The trials will test the efficacy of insulin-sensitizing agents and antioxidants, such as vitamin E, in slowing or reversing disease progression.
A systematic review found that Hepatitis C significantly impacts quality of life, affecting physical and social function, general health and vitality. Researchers established a minimally clinically important difference in vitality scale to monitor patient outcomes.
Research suggests statins can cause asymptomatic elevation of aminotransferases, especially at higher doses, but rare reports of significant liver injury exist; monitoring liver values is recommended for patients on statins, particularly those with known liver conditions.
Scientists have identified two populations of immune cells in the liver that can cause scarring and break it down. This discovery may lead to future treatments for liver damage and cirrhosis, a condition that affects more women in the UK than cervical cancer.
A study of liver transplant patients found that older donors, longer cold ischemia times, and urgent recipient status are significant risk factors for shortened graft survival. The results suggest a new model to predict post-transplant survival, potentially improving organ allocation decisions.
A study of 54 patients with ALD who underwent liver transplants found that those who resumed alcohol consumption had significantly lower 10-year survival rates compared to abstinent patients. Higher mortality rates among relapse group were attributed to increased risk of cancers and cardiovascular events.
A study of liver transplant patients with hepatitis C found that donor age does not impact long-term survival rates. Instead, maintenance azathioprine was associated with improved overall and 3-month survival rates, suggesting a complex relationship between immunosuppression and disease progression.
Researchers have developed a gene therapy that completely cures Crigler-Najjar syndrome, a liver disease, in rats using a specially designed adenovirus. The treatment has no long-term effect and poses no risk of cancer, making it a promising approach for treating other diseases with similar genetic deficiencies.
Researchers identify new therapeutic targets for immune-mediated liver diseases and explore the role of IL-6 in protecting liver cells. Osteopontin is also found to play a central role in amplifying rheumatoid arthritis, suggesting potential new treatments for this inflammatory condition.
Research reveals that IL-6 activates a pathway in liver cells that triggers protection against hepatitis and immune-mediated liver damage. Two proteins, KC and SAA2, play a crucial role in this protective effect.
Researchers discovered that sirtuin1 and PGC1-alpha proteins interact to trigger glucose production in the liver. Targeting this interaction could help control sugar production in people with diabetes, potentially leading to new treatment options.
Researchers have successfully replicated the hepatitis C virus (HCV) in a laboratory setting using a new in vitro model system. The system allows for the study of HCV therapeutics and the entire virus life cycle, including replication, assembly, and release from host cells.
A Pitt researcher has developed a decision-making model to help patients weigh the risks and benefits of accepting organ transplants. The model uses mathematical techniques to provide insight into patient physiology and quality of life, helping doctors make informed decisions.
Researchers found that adding serum sodium to the MELD score significantly increases its accuracy in predicting short-term mortality among liver transplant patients with advanced cirrhosis. The study showed that hyponatremia was a more accurate marker of poor outcome than serum creatinine.
The study found that EGCG protected fatty livers from cell damage after I/R injury, reducing necrosis and increasing viable tissue. It also reduced liver fat content by approximately 55 percent and increased hepatic energy stores.
Researchers found that chronic lymphocytic leukemia (CLL) cells are born at a fast rate but die, leading to a slow rise in cell count over time due to variable birth and death rates. This dynamic interplay between CLL cell division and cell death may enable physicians to predict disease progression.
Researchers found a biochemical switch, PGC-1beta, in liver cells that triggers the harmful effects of saturated and trans fats. The discovery offers hope for developing drug therapies to lower cholesterol levels and heart disease risk.
A study published in Liver Transplantation found that liver disease severity does not accurately predict quality of life, suggesting alternative methods should be considered for organ allocation. Patients with end-stage liver disease experience impaired quality of life, but this is not correlated with MELD scores.
A study of 742 patients with newly diagnosed chronic liver disease found that ethnicity significantly impacts NAFLD prevalence, particularly among Hispanic and Asian populations. The study highlights the need for culturally sensitive education and representation in future clinical studies to address disparities in diagnosis and treatment.
A new study reveals that liver disease can impair learning ability by disrupting the glutamate-nitric oxide-cGMP pathway in the brain. Sildenafil treatment restored learning ability in rats with portacaval shunts and those with hyperammonemia, suggesting a potential therapeutic approach for patients with hepatic encephalopathy.
Researchers have identified two types of immune cells in the liver that can cause scarring or repair it. Understanding these cells may lead to new treatments for cirrhosis, a major cause of liver failure.
Researchers found that transplanted bone marrow cells reduced liver fibrosis in mice treated with carbon tetrachloride. The treatment also improved survival rates and increased serum albumin levels, suggesting a new concept for treating liver fibrosis.
Researchers used 3D MDCT to evaluate patients before surgery and found that abnormal liver artery anatomy increases the risk of complications after a transplant. The study analyzed over 80 patients and found that those with variant anatomy were more likely to experience post-surgical complications.
A multicenter study found that early steroid withdrawal after liver transplantation increased acute rejection rates, but may decrease the risk of long-term cardiovascular disease and mortality. The study suggested that earlier withdrawal could lead to improved glucose tolerance and reduced metabolic complications.
A patient with a 20-year history of heavy drinking underwent liver transplantation in 1999 and experienced progressive recovery of strength in both legs. The authors suggest that peripheral neuropathy in patients with alcoholic cirrhosis is reversible and should not be a contraindication to liver transplantation.
T cells activated during IBD found in PSC livers, re-routed by aberrant attractant protein. Long-lived memory cells may explain delayed liver disease onset after IBD resolution.
Researchers at University of Toronto found evidence of lead contamination resulting from bismuth use in waterfowl samples. The study suggests that excessive bismuth exposure may be linked to blood, liver, kidney and neural problems.
Researchers found that treating mothers with IgG during pregnancy significantly reduced the severity of recurrent NH in newborns. The study showed that all 16 pregnancies progressed uneventfully and resulted in live babies with normal physical examination findings.
Researchers found elevated caspase levels in HCV patients with normal aminotransferase levels, associated with higher stages of liver fibrosis. The study suggests that measuring caspase-mediated CK-18 cleavage in serum may be a more sensitive method to detect liver fibrosis in chronic HCV infection.
Researchers found that combining liver transplantation and coronary artery bypass grafting is a safe approach for patients with severe coronary artery disease and end-stage liver disease. The procedure's success depends on careful multidisciplinary evaluation, coordination, and graft selection.
Researchers demonstrate that long-term maintenance therapy with peginterferon alfa-2b can prevent or delay the progression of hepatitis C, reducing the risk of liver damage by half. A new antiviral agent, NM283, also shows promising activity against genotype 1 HCV, offering hope for future therapies.
A study of nearly 400 African-American patients found that weight-based REBETOL dosing with PEG-INTRON improved viral clearance and reduced relapse rates compared to a flat dose. The treatment showed promise in improving outcomes for this patient population, which has historically had lower response rates to hepatitis C therapy.
A new study finds that combining Pegasys with ribavirin reduces hepatitis C viral levels more effectively than Peg-Intron, a promising development in treating the virus. The study's lead investigator hopes that the findings will inform the design of better drugs to combat the infection.
In a subgroup of high-risk patients, VYTORIN significantly reduced LDL cholesterol by 59% compared to Lipitor. This resulted in more patients achieving an LDL cholesterol goal of less than 100mg/dL with VYTORIN, and increased HDL cholesterol levels.
Researchers at Thomas Jefferson University found a significant decrease in liver rejection rates using a monoclonal antibody, basiliximab, in combination with tacrolimus and low-dose steroids. The one-year survival rate improved to 88%, with no complications reported.
A study found that patients who received liver transplants from living donors are more likely to experience severe Hepatitis C recurrence. The research, led by Xavier Forns, investigated the effect of donor life status on HCV patient outcomes and discovered a significant association between living donor transplantation and severe disea...
Research on hepatitis C patients after liver transplantation found that 10-year outcomes are similar to those for other indications, but risk of recurrence and failure increases over time. Factors such as donor and recipient age, viral load, and CMV antibodies can predict transplant success.
A team of scientists at Scripps Research Institute has discovered a new genetic component of the mammalian clock, known as Rora. This discovery holds promise for understanding circadian rhythms and their role in health and disease, including conditions like jet lag and sleep disorders.
Two young scientists, Matthew R. Jones and Takuya Sakaguchi, have been awarded the APS Postdoctoral Fellowship to investigate the roles of Interleukin-6 in pneumonia infections and liver organogenesis, respectively. The fellowship aims to advance understanding of physiological genomics by integrating cellular and molecular biology.
A team of MCG students has discovered a vegetarian alternative to chicken liver for diagnostic imaging, utilizing Carborite Pancake Mix. The product's binding rate is 97-98%, comparable to that of chicken liver.
Researchers analyzed 15 years of data on liver transplant recipients with hepatitis B and found significant improvements in 5-year-survival rates from 53% to 76%. Advances in prophylaxis and treatment of recurrent HBV disease likely contributed to these gains.
Researchers discovered that inflammatory genes are activated and control bile duct obstruction in biliary atresia, a disease affecting up to 50% of children undergoing liver transplants. Blocking these inflammatory signals may prevent disease progression and increase long-term survival.
Experts disagree on acetaminophen's safety; William M. Lee advocates for stricter regulation to reduce overdoses, while Barry H. Rumack suggests therapeutic doses are safe and most cases may be intentional overdose attempts.
A study found that blacks were underrepresented on liver transplant waiting lists, with only 8.4% of the list being black despite 13.6% of the population being black. Blacks also had higher mortality rates while waiting for transplants and were less likely to receive transplants within 4 years compared to whites.
Researchers at OHSU's Oregon Stem Cell Center have discovered that macrophages, not stem cells, can fuse with diseased liver cells to correct genetic liver disease in mice. This finding suggests that transplantation of macrophages alone may be a more targeted and effective treatment approach than traditional stem cell therapy.
The Mayo Clinic discovery sheds light on the cellular mechanisms behind Non-Alcoholic Fatty Liver Disease (NAFLD), a growing global problem related to affluence and diet. Early signs include accumulation of fat in the liver, inflammation, and scarring, which can lead to impaired function.
A study found that liver damage risk varies by gender and drinking pattern. Women are more susceptible, especially when not eating with alcohol, whereas men's risk depends on frequency and amount of drinking.
Researchers have found that women with visceral fat experience increased lipolysis, the breakdown of fat cells, which can lead to weight loss. The study suggests that this type of fat may be particularly responsive to diet and exercise.
Researchers found that bone marrow stem cells can differentiate into liver cells within days, restoring liver function in injured mice. The study suggests a new approach to treating chronic diseases like diabetes and cirrhosis of the liver.
A recent study published in Hepatology suggests that using nitric oxide during liver reperfusion can protect transplanted livers from cell death, improving survival rates. Researchers found that nitric oxide blocks mitochondrial damage, a key factor in organ rejection and failure.
Researchers have identified a potential new source of stem cells for treating liver damage, offering hope for improved care. The study found that umbilical cord blood cells may differentiate into functional liver cells after transplantation, providing a promising therapeutic avenue for acute and chronic liver injury therapy.
Research has identified improved screening programs for HIV coinfection with chronic hepatitis C, as well as predictive models for inflammation and fibrosis in patients with chronic hepatitis B. These advances aim to improve treatment decisions and quality of life for affected individuals.
A new study published in Liver Transplantation reveals that regional review boards effectively distinguish between high- and low-risk patients, ensuring fair organ allocation. The study also found that referring physicians have poor predictive capacity for patient mortality.
Researchers found an inverse correlation between coffee and caffeine consumption and liver injury, which declined with increasing coffee drinking and caffeine intake. Carbonated soft drink consumption was also linked to a rise in esophageal adenocarcinoma rates, with a strong correlation seen between the two.
Data from over 35,000 organ recipients demonstrated improved patient and graft survival with CellCept-based treatment regimens. The studies found significant improvements in liver and kidney transplant outcomes, reducing infectious deaths and increasing graft survival rates.
Researchers found that liver dendritic cells express less TLR-4, a molecule that triggers immune activation, due to the constant exposure to LPS from gut bacteria. This mechanism may contribute to the liver's inherent tolerogenic potential and lower rejection rates in transplant patients.